公司资料
Orgenesis 股价、新闻与催化剂
- 股票代码:
- ORGS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.10 USD (+205.81%)
收盘价
最后更新: 2026年8月20日
—
市值
股价为何变动
Current closing-price context is not available for ORGS.
公司概览
业务概览
Orgenesis is a cell-therapy and advanced-manufacturing company focused on decentralized manufacturing, point-of-care cell processing, and enabling infrastructure for regenerative medicine. Its story blends therapeutic ambition with platform and services capability.
所在地与行业分类
Orgenesis is headquartered in the United States and listed on NASDAQ, with a global and platform-oriented biotech profile. It sits between cell therapy, manufacturing services, and biotech infrastructure.
商业模式特征
The business model depends on platform partnerships, manufacturing solutions, and the ability to commercialize decentralized cell-therapy workflows. Investors watch strategic deals, platform adoption, and the company's ability to translate infrastructure into revenue.
生物医药行业定位
Orgenesis occupies a niche infrastructure position within biotech. It is less of a classic drug stock and more of a platform-enablement story tied to cell therapy manufacturing.
未来催化剂
- Orgenesis’ catalysts are cell-therapy manufacturing, point-of-care platform execution, and any update that clarifies how the company is monetizing its assets. The story is still mostly about platform commercialization.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。